Company news

BioNTech SE news in 2026

BioNTech SE's news releases, calls and decks from 2026, newest first.

View company

BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update

November 3, 2026

BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer

October 26, 2026

BioNTech and Bristol Myers Squibb Report Encouraging Global Phase 2 Data for Pumitamig in Advanced NSCLC After Progression on Immunotherapy Plus Chemotherapy

October 25, 2026

BioNTech Advances Phase 3 Clinical Trial of Pumitamig in Combination with Gilead’s TROP2-Directed ADC Sacituzumab Govitecan in Triple-Negative Breast Cancer

October 22, 2026

BioNTech and Australia’s State of Victoria Celebrate Milestone in Strategic Partnership to Strengthen mRNA Ecosystem

October 21, 2026

BioNTech to Report Third Quarter 2026 Financial Results and Corporate Update on November 3, 2026

October 20, 2026

BioNTech to Showcase Oncology Late-Stage Pipeline Progress and Pumitamig Novel-Novel Combination Data at ESMO 2026

October 19, 2026

Calls in 2026

Decks in 2026